The Career Development Program of the Mayo Clinic Breast Cancer SPORE is committed to identifying and mentoring junior faculty with the greatest potential of developing independent programs in translational breast cancer research. This will be accomplished through a rigorous review process aimed at identifying the most talented and promising candidate followed by an intensive, rigorous and effective mentoring program. The mentoring program is based on the establishment and optimal functioning of a Multidisciplinary Mentoring Committee led by a senior investigator with the scientific expertise and commitment to developing the next generation of translational breast cancer researchers. The Multidisciplinary Mentoring Committee will be composed of the primary mentor and the complementary clinical and/or basic investigator necessary for a comprehensive mentoring program plus a statistician. It is viewed as crucial to the success of the awardee that the mentoring be ongoing and robust. This will be accomplished by close oversight by the Director of the Career Development Program of the mentoring process and progress of the awardee. The Director of the Career Development Program will report to the SPORE Director who in turn reports to the SPORE Executive Committee. This intensive oversight process was established because of the firm conviction of the SPORE Director that the development of independent investigators and translational breast cancer research is central to the SPORE mission. The explicit expectation is that the awardees will utilize the resources made available to them for the development of independent research programs and acquisition of independent funding in breast cancer research. We are requesting $50,000 per year to support this program. This will be supplemented by $50,000 of Mayo Clinic Cancer Center support. One award of $100,000 per year will be made, which can be used for salary, technician support, and supplies. One awardee will be supported per year and a given awardee can be supported for up to two years providing satisfactory progress is demonstrated. To date the Program has been successful in that the first two Career Development Program awardees have been highly productive and have successfully competed to become Project Co-Leaders in this competitive renewal application.

Public Health Relevance

The Career Development Program is focused on identifying, supporting and mentoring the most highly qualified investigators in basic science, population science and clinical research who have the greatest potential to conduct meaningful translational research in breast cancer and develop independent research programs directed at reducing the burden and mortality from breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-08
Application #
8744968
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-01
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$75,221
Indirect Cost
$25,555
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wiese, Elizabeth K; Hitosugi, Taro (2018) Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect. Front Cell Dev Biol 6:79
Frank, Ryan D; Winham, Stacey J; Vierkant, Robert A et al. (2018) Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer 124:3319-3328
Degnim, Amy C; Winham, Stacey J; Frank, Ryan D et al. (2018) Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. J Clin Oncol 36:1840-1846
Ohmine, Seiga; Salisbury, Jeffrey L; Ingle, James et al. (2018) Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells. Oncol Rep 39:1725-1730
Kourtidis, Antonis; Anastasiadis, Panos Z (2018) Close encounters of the RNAi kind: the silencing life of the adherens junctions. Curr Opin Cell Biol 54:30-36
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Ho, Ming-Fen; Lummertz da Rocha, Edroaldo; Zhang, Cheng et al. (2018) TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor ?B p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther 365:700-710
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574
Reese, Jordan M; Bruinsma, Elizabeth S; Nelson, Adam W et al. (2018) ER?-mediated induction of cystatins results in suppression of TGF? signaling and inhibition of triple-negative breast cancer metastasis. Proc Natl Acad Sci U S A 115:E9580-E9589
Lilyquist, Jenna; Ruddy, Kathryn J; Vachon, Celine M et al. (2018) Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. Cancer Epidemiol Biomarkers Prev 27:380-394

Showing the most recent 10 out of 473 publications